Replicate phase 3 trials show the IL-33-targeting monoclonal antibody reduces moderate and severe exacerbations regardless of blood eosinophil levels or smoking status.

Among patients with COPD and type 2 inflammation at an urgent outpatient visit, the ED or hospital, a single dose of add-on rademikibart vs. placebo lowered treatment failure through 4 weeks, ...

Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT study, while Connect Biopharma said it plans to discuss a Phase 3 ...

Please provide your email address to receive an email when new articles are posted on . Risk estimation was based on area under the receiver operating characteristic curve, sensitivity and specificity ...

The 2026 edition of the GOLD (Global Initiative for Chronic Obstructive Lung Disease) report (v1.3), released in December ...

Explore 10 habits that could be making your COPD worse. If you have chronic obstructive pulmonary disease (COPD), you already know that smoking and eating unhealthy foods can worsen your condition.

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...

Two posters presented at the CHEST Annual Meeting 2023 showed how real-world exacerbation rates in asthma and chronic obstructive pulmonary disease (COPD) dropped after patients started using a single ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

Systemic corticosteroids improve symptoms of acute COPD exacerbations at three days and reduce the likelihood of treatment failure. There is no evidence that they reduce mortality or prevent ...

A population-based cohort study of more than 10,000 persons using gabapentinoids found that their use was associated with an increased risk of chronic obstructive pulmonary disease (COPD) exacerbation ...